Roth Capital Initiates Coverage On MediciNova with Buy Rating, Announces Price Target of $6

Roth Capital analyst Boobalan Pachaiyappan has initiated coverage on MediciNova (NASDAQ: MNOV) with a Buy rating. The firm has set a price target of $6 for the company's stock.